PETITION: Pres. Trump don't give federal funds to COVID-19 vaccines made from aborted baby cellsSign the petition here.
TYLER, Texas, April 24, 2020 (LifeSiteNews) Bishop Joseph Strickland released a pastoral letter asking faithful Catholics to join him in helping to bring to a halt any development of a coronavirus vaccine derived from aborted babies.
Tragically, people are not aware of or have chosen to turn a blind eye to the advances in medical science which allow vaccines to be developed with the wholesale use of aborted childrens bodies, the bishop of Tyler in Northeast Texas wrote on April 23.
He admitted that until recently, I knew very little about the use of in line stem cells from aborted babies in developing vaccines.
Strickland stressed that just because the crime of abortion is considered legal in our nation does not mean it is morally permissible to use the dead bodies of these children to cure a global pandemic. Emphatically, this practice is evil.
As your Shepherd, the bishop wrote, I urge you to join me, NOW, in passionately but prayerfully speaking out against this practice. As I said in the beginning of this letter, I will help you navigate this storm as best as I can.
I ask you to join your voices with mine in an effort to bring to a halt [this] reality.
Strickland announced he will provide a guide to assist you with speaking the truth to all your elected representatives, the pharmaceutical industry, and your local community.
We must insist that legislators create legislation which establishes the illegal and immoral nature of any use of the remains of aborted babies for research, he added. Further, we must insist that pharmaceutical companies comply with such legislation. I believe this can be a significant building block in a culture of life which eliminates the taint of economic gain that too easily infects the abortion industry.
Bishop Strickland explained how the Church has long defended the right to life and love owed to our children. Recent popes have unanimously pointed to the culture of death that is rampant in our world as a threat that we must address.
Pope John Paul II, in his 1995 encyclical Evangelium Vitae, described the dramatic struggle between the culture of life and the culture of death. According to Strickland, the ugly culture of death is exposing itself in an even more serious way during the fight against the COVID-19 pandemic by looking for a vaccine.
Evangelium Vitae points out that the killing of innocent human creatures, even if carried out to help others, constitutes an absolutely unacceptable act. Strickland used this quote in the context of talking about aborted baby body parts to develop a vaccine.
He also proposed a better translation of the term human creatures namely, human persons.
The child in the womb is more than a creature. The child in the womb is a HUMAN PERSON. Just as we are human persons, he wrote.
In addition to Evangelium Vitae, the bishop also recalled the 1987 instruction Donum Vitae, approved by Pope John Paul II and published by Cardinal Joseph Ratzinger, at the time prefect of the Congregation for the Doctrine of the Faith. But what is technically possible is not for that very reason morally admissible, the instruction stated.
As Strickland pointed out, ethical means are available and can prove to be just as effective in developing vaccines; umbilical cells, placental cells, adult stem cells and other sources of cells, including even those of insects, provide completely viable paths to an effective vaccine.
LifeSiteNews reported on research by pro-life group Children of God for Life, which focuses on the question of ethical vaccines, showing how one company, Sanofi, is using a platform based on insect cells. Their Sf9 cell line comes from the fall armyworm and is highly effective as a rapid growth medium. It has been used for several years in producing influenza vaccines.
Strickland said, Scientists Ive spoken with assure me that there is no medical necessity for using aborted children in order to develop the much-needed vaccine to protect us from this particular strain of Coronavirus.
Earlier in April, the bishop of Tyler had already said he will refuse a potential vaccine for the coronavirus if it is made using tissue from aborted children. He expressed his sadness over the fact that even with Covid-19 we are still debating the use of aborted fetal tissue for medical research.
Several Catholic bishops and pro-life leaders sent an open letter to the U.S. Food and Drug Administration last Friday, asking the government agency to ensure that Americans will have access to coronavirus vaccines that are free from any connection to abortion.
To be clear, we strongly support efforts to develop an effective, safe, and widely available vaccine as quickly as possible, the letter stated. However, we also strongly urge our federal government to ensure that fundamental moral principles are followed in the development of such vaccines, most importantly, the principle that human life is sacred and should never be exploited.
Among the signers was Archbishop Joseph F. Naumann of Kansas City, chairman of the United States Conference of Catholic Bishops Committee on Pro-Life Activities, as well as laypeople, including Jeanne Mancini, organizer of the yearly March for Life in the nations capital, Michael Farris of Alliance Defending Freedom, and Lila Rose of pro-life organization Live Action.
Bishop Strickland praised the letter for indicating our immediate task ... to demand ethical vaccines for COVID-19.
We must go further, however, and pursue the prevention of future development of vaccines using remnants and available cells of aborted childrens bodies and to use only ethically developed vaccines, he added.
Strickland concluded his April 23 letter by urging the faithful to pray with me for Gods conversion of hearts which is the ultimate remedy for the culture of death in which we continue to be immersed.
Read more:
- Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therapy for Juvenile Idiopathic Arthritis - Business... - December 22nd, 2024
- What Are Stem Cells? Biomedical Beat Blog National Institute of ... - November 29th, 2024
- TVHS opens stem cell processing lab to expand biotherapies | VA Tennessee Valley health care | Veterans Affairs - Veterans Affairs - November 8th, 2024
- Understanding Mature Tissue or Organ Stem Cells and Their Clinical ... - November 8th, 2024
- Biology of stem cells: an overview - PMC - PubMed Central (PMC) - October 30th, 2024
- New government tech deals boost the business of cancer detection - GOV.UK - October 11th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - Yahoo News UK - October 11th, 2024
- Advances in different adult stem cell-derived exosomal non-coding RNAs for the treatment of neurological disorders: a narrative review - Frontiers - September 26th, 2024
- Breakthrough technique may help speed understanding, treatment of MD, ALS - Harvard Gazette - September 14th, 2024
- Rostock University Explores Use of Stem Cells for Meat Cultivation with Help from Innocent Meat - vegconomist - the vegan business magazine - August 12th, 2024
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - July 31st, 2024
- Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - July 31st, 2024
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - July 31st, 2024
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 - July 31st, 2024
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 - July 31st, 2024
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 - July 31st, 2024
- Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency... - July 31st, 2024
- Targeting the stem cell niche micro-environment as therapeutic strategies in aging - Frontiers - June 28th, 2024
- International trial introduces another curative option for sickle cell disease - EurekAlert - June 28th, 2024
- HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation - Frontiers - June 28th, 2024
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and... - June 21st, 2024
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - June 21st, 2024
- Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. - June 21st, 2024
- Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer - June 21st, 2024
- API and the University of Alberta Break Ground in Edmonton on Canada’s Largest Manufacturing Facility for Critical Medicines - June 21st, 2024
- Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems - June 21st, 2024
- Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform - June 21st, 2024
- Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog... - June 21st, 2024
- Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting - June 21st, 2024
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing - June 21st, 2024
- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran - June 21st, 2024
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’... - June 21st, 2024
- Radiopharm Receives Strategic Investment for up to A$18 million - June 21st, 2024
- Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee - June 21st, 2024
- Trading by management and close relations of management - June 21st, 2024
- Major shareholder announcement - June 21st, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 21st, 2024
- Nature retracts highly cited 2002 paper that claimed adult stem cells could become any type of cell - Retraction Watch - June 19th, 2024
- Shares of Biotech MicroCap Rip on Licensing Talks - The Globe and Mail - June 15th, 2024
- Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 - May 23rd, 2024
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 23rd, 2024
- Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist... - May 23rd, 2024
- Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus... - May 23rd, 2024
- Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 - May 23rd, 2024
- New York Blood Center Enterprises Celebrates the Expansion of Cell & Gene Therapy GMP Manufacturing Capabilities at the Grand Opening of... - May 23rd, 2024
- Syneos Health Leaders Recognized as PM360 ELITE 100 Award Recipients - May 23rd, 2024
- Kane Biotech Announces First Quarter 2024 Financial Results - May 23rd, 2024
- Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast - May 23rd, 2024
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy - May 23rd, 2024
- Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024 - May 23rd, 2024
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - May 23rd, 2024
- Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - May 23rd, 2024
- Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024 - May 23rd, 2024
- Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences - May 23rd, 2024
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - May 23rd, 2024
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual... - May 23rd, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
Recent Comments